Guidelines: COVID-19 Drug Therapy Trial Updates
Guideline Resources
COVID-19 Drug Therapy Trial Updates
Key Points
Updated 9/24/20. No drug is currently FDA-approved to treat COVID-19. Many drugs have reported in vitro activity or theoretical basis for antiviral activity. Some agents have encouraging evidence demonstrating clinical efficacy. All trial links in this resource lead to pre-filtered search results (by drug) at ClinicalTrials.gov.

Which aspects of this resource are most valuable to you (trial results, expanded access details, links to clinical trials)? Share your feedback with epocrates.
Choose Investigational Tx
Epocrates researched Rx drug content. Peer-reviewed.
Epocrates Guideline Synopsis Last Update: Sep 24, 2020
Publication Year:
2020
Source:
epocrates
Abbreviations
Abantibody
ACEIangiotensin-converting enzyme inhibitor
ARBangiotensin receptor blocker
AZazithromycin
CIconfidence interval
COVID-19coronavirus dz 2019
CScorticosteroid
DRV/cdarunavir/cobicistat
EHRelectronic health record
FPVfavipiravir
HCQhydroxychloroquine
HCWhealth care worker(s)
IFNinterferon
LMWHlow-molecular-weight heparin
LOSlength of stay
LPV/r lopinavir/ritonavir
NCnasal cannula
NOnitric oxide
NTZnitazoxanide
RAroom air
RCTrandomized, controlled trial
RDVremdesivir
SOCstandard of care
SOFAsequential organ failure assessment
TCZtocilizumab
TXAtranexamic acid